- Precigen Reports Full Year 2023 Financial Results and Business Updates
- Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
- Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
- Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
More ▼
Key statistics
As of last trade Precigen Inc (PGEN:NSQ) traded at 1.44, -23.67% below its 52-week high of 1.88, set on Aug 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.43 |
---|---|
High | 1.47 |
Low | 1.42 |
Bid | 1.43 |
Offer | 1.44 |
Previous close | 1.45 |
Average volume | 1.18m |
---|---|
Shares outstanding | 248.92m |
Free float | 220.75m |
P/E (TTM) | -- |
Market cap | 360.93m USD |
EPS (TTM) | -0.3933 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 18:42 BST.
More ▼